Contraceptive and dysmenorrheal relief efficacy of single rod etonogestrel implant (Implanon

Abstract

Objective To evaluate the contraceptive and dysmenorrheal relief efficacy, and safety of single rod Etonogestrel implant (Implanon). Methods A total of 200 females who received single rod Etonogestrel implant for contraception were enrolled. The participants were followed up for 24 months to evaluate the contraceptive efficacy, relief rate of dysmenorrheal, side effects and continuation rate of Implanon. Results A total of 190 participants finished the 24-month follow-up. During the period, the contraceptive efficacy was 100%, and the relief rate of dysmenorrheal was 90.2%(55/61). The major side effects were menstrual changes (141/190, 74.2%), including irregular bleeding (60/190, 31.6%), amenorrhea (6/190, 3.2%), prolonged bleeding (63/190, 33.2%), frequent bleeding (41/190, 21.6%), infrequent bleeding (20/190, 10.5%), decreased volume of bleeding (66/190, 34.7%), and increased volume of bleeding (10/190, 5.3%). Other side effects included gaining weight (32/190, 16.8%), acne (21/190, 11.1%), and hormone-associated side effects (63/190, 33.2%). During the follow-up, a total of 16 participants terminated implanon at an early stage, including 10 cases of irregular bleeding and 6 cases of amenorrhoea, yielding a continuation rate of 91.6%. Conclusion Single rod Etonogestrel implant (Implanon) is effective and safe in contraception with relieved dysmenorrheal and a high continuation rate. Key words: Etonogestrel; Contraception; Safety; Continuation rate